Skip to main content

  • Outcomes of transcatheter aortic valve replacement in patients with and without amyloidosis: A nationwide analysis from the United States

    • Posted: 01/03/2024
    • Author:

      Mahmoud Ismayl, Muhannad Abbasi, Abdullah Al-Abcha, Edward El-Am, Mohamad Alkhouli, Mayra Guerrero, Angela Dispenzieri, Vuyisile T. Nkomo, Omar F. Abou Ezzeddine, Martha Grogan and Nandan S. Anavekar

    • 2024CRM

    Abstract

    Background

    Amyloidosis is a common comorbidity in elderly patients with aortic stenosis (AS) referred for transcatheter aortic valve replacement (TAVR). This study aims to assess the impact of amyloidosis on the clinical outcomes of TAVR.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details